Morepen to add 1,000 medical representatives

The company is targeting a Rs. 1,000 crore finished dosages business within the next five years

Metropolis to acquire Dehradun’s Ahujas’ Pathology & Imaging Centre for Rs. 35.01 Cr

Enhertu approved in EU in post-ET breast cancer

Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease

Glenmark Pharmaceuticals USA launches Vancomycin Hydrochloride for Injection

According to IQVIA sales data for the 12-month period ending January 2025, the Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial) market achieved annual sales of approximately $39.3 mn

Morepen secures Loratadine approval for export to China

This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets

DKSH Technology acquires Korean life science firm MDxK

The acquisition of MDxK further strengthens the Business Unit’s position in the molecular diagnostics market

Mila Beaute raises $2.16 million in pre-series A round led by Rukam Capital

The freshly infused capital will primarily be deployed towards expansion and research & development

Glenmark receives ANDA approval for Olopatadine Hydrochloride ophthalmic solution USP, 0.2%

Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), will be distributed in the US by Glenmark Therapeutics, USA.

Zydus receives final approval from USFDA for Apalutamide Tablets, 60 mg

Apalutamide is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive prostate cancer

CKD cases surge to 16.38% in Indians aged 15+

Experts urge early detection & better access to care